Literature DB >> 9582148

Adjuvant tamoxifen: how long before we know how long?

D Rea1, C Poole, R Gray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9582148      PMCID： PMC1113163          DOI： 10.1136/bmj.316.7143.1518

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

Authors:  B Fisher; J Dignam; J Bryant; A DeCillis; D L Wickerham; N Wolmark; J Costantino; C Redmond; E R Fisher; D M Bowman; L Deschênes; N V Dimitrov; R G Margolese; A Robidoux; H Shibata; J Terz; A H Paterson; M I Feldman; W Farrar; J Evans; H L Lickley
Journal:  J Natl Cancer Inst       Date:  1996-11-06       Impact factor: 13.506

2.  Five years of tamoxifen--or more?

Authors:  R Peto
Journal:  J Natl Cancer Inst       Date:  1996-12-18       Impact factor: 13.506

3.  Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1996-11-06       Impact factor: 13.506

4.  Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1996-12-18       Impact factor: 13.506

5.  Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.

Authors:  D C Tormey; R Gray; H C Falkson
Journal:  J Natl Cancer Inst       Date:  1996-12-18       Impact factor: 13.506

6.  Sudden fall in breast cancer death rates in England and Wales.

Authors:  V Beral; C Hermon; G Reeves; R Peto
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321

Review 7.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

8.  Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.

Authors:  C C McDonald; H J Stewart
Journal:  BMJ       Date:  1991-08-24

9.  Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years.

Authors:  R R Love; R B Mazess; D C Tormey; H S Barden; P A Newcomb; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1988-12       Impact factor: 4.872

10.  Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.

Authors:  H J Stewart; A P Forrest; D Everington; C C McDonald; J A Dewar; R A Hawkins; R J Prescott; W D George
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640
  10 in total
  3 in total

1.  Gynaecological effects of tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

2.  More large trials needed to decide best duration of treatment with tamoxifen.

Authors:  D A Cameron
Journal:  BMJ       Date:  1998-11-28

3.  Potential anti-genotoxic effect of sodium butyrate to modulate induction of DNA damage by tamoxifen citrate in rat bone marrow cells.

Authors:  Haidan M El-Shorbagy
Journal:  Cytotechnology       Date:  2016-11-30       Impact factor: 2.058
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.